Evaluation of the Bronchoprotective Effect of Arformoterol in Children With Exercise Induced Bronchospasm (EIB)

NCT00662779 Phase 3 WITHDRAWN

It is our primary hypothesis that pretreatment with arformoterol will provide superior protection against EIB in children with mild-moderate asthma compared to placebo added to the current asthma regimen. Our secondary hypothesis is that nebulized arformoterol has comparable protection against EIB compared to inhaled formoterol by dry powder inhaler.

Details

Lead sponsor	University of New Mexico
Phase	Phase 3
Status	WITHDRAWN
Start date	2008-04
Completion	2009-07

Conditions

• Exercise-induced Bronchospasm

Interventions

• arformoterol
• formoterol
• placebo

Primary outcomes

• It is our primary hypothesis that pretreatment with arformoterol will provide superior protection against EIB in children with mild-moderate asthma compared to placebo added to the current asthma regimen. — April 2008-April 2010

Countries

United States